AbCellera Biologics Inc. (ABCL)
|52 Week Range||4.67-14.97|
|1y Target Est||-|
|DCF Unlevered||ABCL DCF ->|
|DCF Levered||ABCL LDCF ->|
|Debt / Equity||7.03%||Neutral|
Upgrades & Downgrades
Latest ABCL news
3 AI Stocks You'll Regret Not Buying Soon
8 August 2023
Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatment, creating big opportunities for these top AI sto...
AbCellera Biologics Inc. (ABCL) Q2 2023 Earnings Call Transcript
3 August 2023
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - Chief Executive Of...
Does AbCellera Biologics Inc. (ABCL) Have the Potential to Rally 242.09% as Wall Street Analysts Exp...
25 July 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 242.1% in AbCellera Biologics Inc. (ABCL). While the effectiveness of this highly sought-after metric is questi...
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom
8 July 2023
AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been an asset to biological research and drug discovery.
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
29 May 2023
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023.
7 Growth Stocks That Could Double Your Money in 2023
14 May 2023
While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept so...
AbCellera Biologics: TCE Program Alone Could Be Worth More Than The Current Market Cap
6 May 2023
AbCellera reported results from the first quarter on May 4th. To put it bluntly, the actual earnings print means next to nothing in this name at this stage. The company had a very busy and productive ...
AbCellera Biologics Inc. (ABCL) Q1 2023 Earnings Call Transcript
4 May 2023
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - Chairman, Chief ...
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates
4 May 2023
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.54 per share a year ago.